Active Autophagy Suppression in Aging Serves to Contain Lysosomal Fragility and Prevent Pro‑Inflammatory DAMP Release

Aged cells deliberately dampen autophagy not because the machinery is broken, but to limit the danger posed by fragile lysosomes that accumulate over a lifetime of oxidative stress. When lysosomal membranes become permeabilized, cathepsins and other hydrolases spill into the cytosol, triggering inflammasome activation and a sterile inflammatory response. By keeping autophagic flux low, the cell reduces the delivery of cargo to lysosomes, thereby lowering the internal pressure that promotes membrane rupture. This creates a trade‑off: short‑term survival is favored at the cost of long‑term accumulation of damaged proteins and organelles.

The mechanism builds on the mTORC1‑centric suppression described in the literature but adds a lysosomal‑stability checkpoint. Persistent mTORC1 activation in senescent cells not only blocks ULK1 and sequesters TFEB; it also phosphorylates the lysosomal lipid‑binding protein LAMP2A, stabilizing its interaction with lysosomal glycoproteins and reinforcing membrane integrity. Simultaneously, age‑related rise in ceramide levels promotes formation of lipid microdomains that further resist permeabilization. Together, these modifications create a lysosomal environment that is less prone to leak, even as autophagosome formation is curtailed.

A testable prediction follows: artificially inducing lysosomal fragility in young cells (e.g., with low‑dose LLOMe) should trigger a compensatory upregulation of autophagy via TFEB nuclear translocation, whereas the same intervention in aged cells will fail to activate autophagy unless lysosomal stabilizers are first inhibited. Conversely, pharmacologically destabilizing lysosomal membranes in aged tissue (using sub‑toxic doses of siramesine) should restore autophagic flux and reduce senescent cell burden, but only if the downstream inflammasome pathway is blocked to prevent cytokine‑driven toxicity.

Experimentally, one can measure lysosomal permeability using galectin‑3 puncta formation in primary hepatocytes from young and old mice, correlate those readings with LC3‑II turnover after bafilomycin A1 treatment, and assess whether Manumycin‑A (a ceramide synthase inhibitor) increases both permeability and autophagic flux in aged cells. Rescue experiments would involve TFEB overexpression or LAMP2A phospho‑mutants that mimic the dephosphorylated state; if autophagy rebounds and senescence markers decline without a surge in IL‑1β or HMGB1 release, the hypothesis gains support. Failure to observe increased autophagy despite lysosomal destabilization would falsify the idea that suppression is primarily a protective containment strategy.